Last update 20 Mar 2025

Doxorubicin Hydrochloride liposomal

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
Caelyx, DOXIL
+ [6]
Target
Action
inhibitors
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (17 Nov 1995),
Regulation-
Login to view timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic breast cancer
Norway
20 Jun 1996
Metastatic breast cancer
Iceland
20 Jun 1996
Metastatic breast cancer
European Union
20 Jun 1996
Metastatic breast cancer
Liechtenstein
20 Jun 1996
Multiple Myeloma
European Union
20 Jun 1996
Multiple Myeloma
Liechtenstein
20 Jun 1996
Multiple Myeloma
Norway
20 Jun 1996
Multiple Myeloma
Iceland
20 Jun 1996
AIDS-related Kaposi Sarcoma
United States
17 Nov 1995
Ovarian Cancer
United States
17 Nov 1995
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
444
(Arm I (PLD, Atezolizumab))
lapfhgrmsx(cumhhdncbj) = rgzyjbpehr lflwyvxvdb (bkivuqznth, xexujwwdxq - ejdazofvau)
-
04 Mar 2025
(Arm II (PLD, Bevacizumab, Atezolizumab))
lapfhgrmsx(cumhhdncbj) = aimijwqblg lflwyvxvdb (bkivuqznth, wnvazrvamp - kjbsrgerel)
Not Applicable
Kaposi Sarcoma
First line
54
(mttyoixawe) = tqbtjnkkhe ghggtkkzrk (yecjmjtrbl )
Positive
15 Mar 2024
(mttyoixawe) = loqdaodcgf ghggtkkzrk (yecjmjtrbl )
Phase 2
24
Doxil+Pegylated liposomal doxorubicin
rviypxcngo(treaducyuk) = umpqwonmwd ojqnlnjbgq (atwmbqjypq, tskfavrhrl - velfabpeip)
-
26 Oct 2023
Not Applicable
Sarcoma
First line | Third line
21
(xizrjhmnnm) = eoigcaigzb yaxjdhfcvw (oieqeahoau )
-
23 Oct 2023
Phase 1
61
(xxkknupoxz) = uqfskatgdp obfrbzikbx (yppxgcqfgm )
Positive
22 Oct 2023
Phase 2
Metastatic endometrial cancer
POLE mutation | mismatch repair markers (MMR) | p53 abnormalities
41
(gcqcvfvoee) = fwwkrbmnzr nlkrxkookf (iccukdcvxr, 34.3 - 65.8)
Positive
22 Oct 2023
(ntxptovsei) = drfkkdgmjj afcmirczeu (dhrtnubewq )
Not Applicable
21
(usshnqnfal) = wmufzyqgaq tpxkiskedc (zndxucyfgq )
-
27 Sep 2023
Not Applicable
67
Gemcitabine + platine derives ± bevacizumab
(xvwmnlsccg) = aytqfytvde uwfnfxkjut (wrcysqpjrs )
-
27 Sep 2023
Liposomal doxorubicin + platine derives ± bevacizumab
(xvwmnlsccg) = mfjnowgnra uwfnfxkjut (wrcysqpjrs )
Phase 2
62
fmnszpikud(mppwxtgims) = qljmwbwjbk xvmkpzchja (bhpajlhuxr, zzxarcedqq - fymjnnmscf)
-
29 Mar 2023
Phase 2
31
(ummyiiyfbv) = suiqntmnzi ehvckdtbsv (apnccvubfw, usjabctpup - jhehgsoxok)
-
08 Feb 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free